张磊，主任医师，博士研究生导师，长期从事血液病临床及基础工作，在专业领域做出了一系列原创性成果。在NEJM，BMJ，Nat Med等国内外知名期刊发表SCI论文百余篇，获得国家发明专利8项。曾获2009年度国家科技进步二等奖、2023年度天津市科学技术进步一等奖等国家级及省部级奖项9项。获得国家科技创新领军人才、天津市杰出人才等项目资助。获国务院政府特殊津贴专家、国家卫生健康突出贡献中青年专家等称号。

长期从事出凝血疾病以及基因治疗方面的研究。牵头开展亚洲首项血友病基因治疗临床试验，全球首次实现基因治疗患者安全接受大手术，牵头完成8项基因治疗临床研究，治愈百余名重症血友病患者，并推动中国首个血友病基因治疗产品注册试验进入III期临床；利用新型CD38单抗实现血小板减少症的持续稳定治愈。相关成果入选年度“中国十大医学科技新闻”和“血液学十大研究进展”等。在NEJM，BMJ，Nat Med等国际顶尖期刊发表SCI论文百余篇。培养博士、硕士、博士后30余名。

中国足球彩票

1. Xue F#, Ju M#, Zhu T#, Zhou Z#, Sun J, Yang L, Yan Z, Zhou H, Du X, Zheng C, Zheng J, Wu X, Du Z, Jiang W, Yang C, Xiao X, Liu W, Yang R, Zhang L*. Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials. Nature Medicine. 2025 Nov 20. Online ahead of print. (IF=50.319, PIII)

2. Chen Y#, Xu Y#, Dai J#, Sun T#, Li H#, Hua Z#, Zhou Z, Zhou H, Yan Z, Zhao X, Xue F, Liu W, Liu X, Fu R, Wang W, Chi Y, Dong H, Ju M, Dai X, Gu W, Pei X, Yang R, Zhang L*. Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial. British Medical Journal. 2025 Oct 21;391:e084314. ( IF=42.7)

3. Sun T#, Chen Y#, Zhang L*. Daratumumab in Relapsed or Refractory Pediatric Immune Thrombocytopenia. New England Journal of Medicine. 2025 May 29;392(20):2069-2071. (IF=96.2)

4. Chen Y#, Xu Y#, Li H#, Sun T#, Cao X#, Wang Y, Xue F, Liu W, Liu X, Dong H, Fu R, Dai X, Wang W, Ma Y, Song Z, Chi Y, Ju M, Gu W, Pei X, Yang R, Zhang L*. A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia. New England Journal of Medicine. 2024 Jun 20;390(23):2178-2190. (IF=96.2)

5. Chen Y#, Xu Y#, Chi Y#, Sun T#, Gao Y#, Dou X, Han Z, Xue F, Li H, Liu W, Liu X, Dong H, Fu R, Ju M, Dai X, Wang W, Ma Y, Song Z, Gu J, Gong W, Yang R, Zhang L*. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial. Signal Transduction and Targeted Therapy. 2024 Apr 23;9(1):102. (IF=40.8)

6. Zhang L#*. Gene therapy in China: past, present, and future. Lancet Haematology. 2022 Dec;9(12):e869-e871. (IF=24.7)

7. Xue F#, Wang P#, Yuan Z#, Shi C, Fang Y, Liu W, Wang Y, Xiao X, Yang R, George LA, Zhang L*. Total Knee Arthroplasty after Gene Therapy for Hemophilia B. New England Journal of Medicine. 2022 Oct 27;387(17):1622-1624. (IF=158.5)

8. Xue F#, Li H#, Wu X#, Liu W#, Zhang F, Tang D, Chen Y, Wang W, Chi Y, Zheng J, Du Z, Jiang W, Zhong C, Wei J, Zhu P, Fu R, Liu X, Chen L, Pei X, Sun J, Cheng T, Yang R*, Xiao X*, Zhang L*. Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial. Lancet Haematology. 2022 Jul;9(7):e504-e513. (IF=24.7)

9. Tong J#, Sun T#, Ma S#, Zhao Y#, Ju M#, Gao Y, Zhu P, Tan P, Fu R, Zhang A, Wang D, Wang D, Xiao Z, Zhou J, Yang R, Loughran SJ, Li J, Green AR, Bresnick EH, Wang D, Cheng T*, Zhang L*, Shi L*. Hematopoietic Stem Cell Heterogeneity Is Linked to the Initiation and Therapeutic Response of Myeloproliferative Neoplasms. Cell Stem Cell. 2021 Mar 4;28(3):502-513.e6. (IF=25.269)

10. Jiang H, Yu Z, Ding N, Yang M, Zhang L, Fan X, Zhou Y, Zou Q, Hou J, Zheng J, Zhang L*, Xu Y*, Liu J*. The role of AGK in thrombocytopoiesis and possible therapeutic strategies. Blood. 2020 Jul 2;136(1):119-129. (IF=22.113)